Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Inflammatory bowel disease: what is new?

P Marteau1, F Daniel, P Seksik

  • 1Department of Gastroenterology, Georges Pompidou European Hospital, Paris, and University of Paris V, France. philippe.marteau@hop-egp.ap-hop-paris.fr

Endoscopy
|February 7, 2004
PubMed
Summary

This review covers recent inflammatory bowel disease research, focusing on gut bacteria, advanced imaging, and predicting treatment success for infliximab and new therapies like natalizumab.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Subcutaneous Infliximab for Perianal Crohn's Disease: The BioLap-Rem Multicenter Study From the GETAID.

The American journal of gastroenterology·2025
Same author

Clinical, Radiological and Pharmacokinetic Data of CT-P13 Subcutaneous in Individuals with Fistulizing Anoperineal Crohn's Disease.

Digestive diseases and sciences·2025
Same author

The double burden of severe mental illness and cancer: a population-based study on colorectal cancer care pathways from screening to end-of-life care.

Epidemiology and psychiatric sciences·2024
Same author

Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO.

ESMO open·2021
Same author

A guide for assessing the clinical relevance of findings in small bowel capsule endoscopy: analysis of 8064 answers of international experts to an illustrated script questionnaire.

Clinics and research in hepatology and gastroenterology·2021
Same author

Defining and Assessing the Reproducibility of Crohn's Disease Endoscopic Lesions: A Delphi-like Method from the GETAID.

Journal of Crohn's & colitis·2020

Area of Science:

  • Gastroenterology and Immunology
  • Molecular Biology and Genetics

Background:

  • Inflammatory Bowel Disease (IBD) encompasses Crohn's disease and ulcerative colitis, complex conditions with significant unmet needs.
  • Advances in understanding IBD pathogenesis and treatment are rapidly emerging, necessitating regular reviews of the latest findings.

Purpose of the Study:

  • To summarize key advancements in inflammatory bowel disease research published between April 2002 and August 2003.
  • To highlight progress in understanding the role of gut microbiota, genetic factors, and diagnostic tools.
  • To review novel therapeutic strategies and factors influencing treatment response in IBD.

Main Methods:

  • Systematic review of 50 selected scientific papers on inflammatory bowel disease.
  • Focus on research concerning bacterial roles, CARD15/NOD2 gene interactions, probiotics, and imaging techniques.

Related Experiment Videos

  • Analysis of studies on predicting efficacy and tolerance of infliximab and emerging treatments.

    • Main Results:

    • Significant progress in understanding the interplay between gut bacteria, CARD15/NOD2 gene products, and the effects of probiotics.
    • Introduction and evaluation of novel diagnostic modalities including wireless capsule endoscopy, chromoendoscopy for dysplasia detection, and fecal markers.
    • Identification of factors influencing the efficacy and tolerance of infliximab and new agents like natalizumab, thalidomide, cyclophosphamide, and 6-thioguanine.

    Conclusions:

    • The review underscores the growing importance of the gut microbiome and host genetics in IBD.
    • New imaging and fecal markers offer improved diagnostic capabilities for IBD and dysplasia.
    • Emerging therapies and predictive markers are crucial for optimizing IBD management.